| Literature DB >> 33344390 |
Vijai Williams1, Nisha Menon1, Prateek Bhatia2, Manisha Biswal3, Sreejesh Sreedharanunni4, Amit Rawat5, Muralidharan Jayashree1, Karthi Nallasamy1.
Abstract
Objective: To evaluate serial ferritin levels measured in the initial 72 h of admission as a biomarker for new and progressive multi organ dysfunction syndrome (NPMODS) and mortality (unfavorable outcomes) in critically ill children with sepsis due to tropical infections. Material andEntities:
Keywords: ferritin; mortality; organ dysfunction; pediatric; predictor; scoring; sepsis; tropical infections
Year: 2020 PMID: 33344390 PMCID: PMC7747694 DOI: 10.3389/fped.2020.607673
Source DB: PubMed Journal: Front Pediatr ISSN: 2296-2360 Impact factor: 3.418
Figure 1Study flow diagram.
Baseline clinical characteristics and etiology.
| Age in years | 5 (2.5, 8) | 5 (2.5, 8) | 3 (2,7) | 0.11 |
| Boys, | 109 (54) | 91 (55.2) | 18 (48.6) | 0.47 |
| Weight in kg | 15 (11.2, 21) | 16 (12, 23) | 13 (10, 20) | 0.06 |
| Weight in Z score | −1.4 (−2.4, −0.6) | −1.4 (−2.3, −0.6) | −1.7 (−2.5, −0.6) | 0.25 |
| PRISM III | 8 (5, 12) | 7 (5, 10) | 15 (11, 18) | 0.001 |
| Duration of illness in days | 5 (4, 7) | 6 (4, 7) | 5 (3, 8) | 0.24 |
| Fever | 202 (100) | 165 (100) | 37 (100) | 1.0 |
| Edema | 88 (43.6) | 72 (43.6) | 16 (43.2) | 0.96 |
| Abdominal pain | 80 (39.6) | 70 (42.4) | 10 (27) | 0.08 |
| Fast breathing | 46 (22.8) | 40 (24.2) | 6 (16.2) | 0.29 |
| Altered sensorium | 47 (23.3) | 25 (15.2) | 22 (59.5) | 0.0001 |
| Seizures | 35 (17.3) | 21 (12.7) | 14 (37.8) | 0.0001 |
| Purpuric rash | 39 (19.3) | 30 (18.2) | 9 (24.3) | 0.39 |
| Bleeding manifestations | 61 (30.2) | 45 (27.3) | 16 (43.2) | 0.05 |
| Oliguria | 16 (7.9) | 13 (7.9) | 3 (8.1) | 0.96 |
| Hepatomegaly | 155 (76.7) | 128 (77.6) | 27 (73) | 0.55 |
| Splenomegaly | 68 (33.7) | 55 (33.3) | 13 (35.1) | 0.83 |
| Scrub typhus | 59 (29.2) | 48 (29.1) | 11 (29.7) | 0.94 |
| Dengue | 41 (20.3) | 37 (22.4) | 4 (10.8) | 0.11 |
| Malaria | 12 (5.9) | 10 (6.1) | 2 (5.4) | 0.88 |
| Enteric fever | 7 (3.5) | 6 (3.6) | 1 (2.7) | 0.78 |
| Japanese encephalitis | 1 (0.5) | 1 (0.6) | 0 (0) | 0.63 |
| No specific diagnosis | 69 (34.2) | 51 (30.9) | 18 (48.7) | 0.03 |
| Dengue and scrub typhus | 11 (5.4) | 10 (6.1) | 1 (2.7) | 0.69 |
| Malaria and scrub typhus | 2 (1.0) | 2 (1.2) | 0 (0) | 0.5 |
All values expressed as Median (IQR).
PRISM, Pediatric Risk of Mortality.
Laboratory investigations of the study population.
| Hemoglobin, g/dl | 202 | 9.4 (7.7, 11.5) | 9.7 (8.1, 11.7) | 7.2 (6.6, 8.7) | 0.07 |
| Total leukocyte count, cells/mm3 | 202 | 11,300 (6,715, 16,107) | 10,940 (6,400, 15,900) | 11,900 (7,280, 20,100) | 0.52 |
| Platelet count, cells/mm3 | 202 | 42,500 (18,550, 87,750) | 42,000 (18,000, 82,000) | 44,000 (27,000, 10,900) | 0.45 |
| Total bilirubin, mg/dl | 127 | 0.7 (0.4, 1.8) | 0.7 (0.4, 1.5) | 1.4 (0.6, 3.6) | 0.03 |
| Aspartate transaminase (AST), U/L | 163 | 185 (104, 364) | 172 (92, 322) | 327 (153, 2,187) | 0.005 |
| Alanine transaminase (ALT), U/L | 160 | 88 (45, 195) | 77 (44, 135) | 134 (82, 582) | 0.004 |
| International normalized ratio (INR) | 137 | 1.2 (1.0, 1.5) | 1.15 (1.0, 1.3) | 1.7 (1.3, 2.7) | 0.0001 |
| Albumin, g/dl | 142 | 2.4 (2, 2.7) | 2.5 (2.2, 2.8) | 2.2 (2, 2.7) | 0.0001 |
| Creatinine, mg/dl | 202 | 0.4 (0.3, 0.6) | 0.4 (0.25, 0.5) | 0.5 (0.3, 0.8) | 0.001 |
| Lactate, mmol/L | 191 | 2.5 (1.5, 3.8) | 2.4 (1.5, 3.4) | 3.4 (2.3, 6.0) | 0.0001 |
| Severe hypoalbuminemia (<2.5 g/dl), | 142 | 75 (52.8) | 56 (48.7) | 19 (70.4) | 0.04 |
| Coagulopathy (INR>1.5), | 139 | 107 (77) | 94 (83.9) | 13 (48.1) | 0.0001 |
| Elevated ALT, (>2 times IU), | 162 | 40 (24.7) | 26 (20) | 14 (43.8) | 0.005 |
| Day 1 Ferritin, μg/L | 183 | 798 (378, 3,205) | 707 (365, 2,937) | 1,381 (433, 5,410) | 0.39 |
| Day 3 Ferritin, μg/L | 120 | 429 (213, 680) | 432 (214, 653) | 254 (209, 1,030) | 0.99 |
| Percentage change in ferritin | 120 | 44 (19, 70) | 46 (19, 72) | 44 (21, 67) | 0.98 |
All values expressed as Median (IQR).
Organ dysfunction and therapy details.
| 202 | 47 (23.2) | 10 (6.0) | 37 (100) | 0.0001 | |
| N-MODS | 22 | 4 (2.0) | 4 (2.4) | 0 (0) | 0.34 |
| P-MODS | 180 | 43 (21.3) | 6 (3.6) | 37 (100) | 0.0001 |
| Day 1 | 202 | 2 (2, 3) | 2 (2, 4) | 4 (3, 4) | 0.0001 |
| Day 2 | 198 | 2 (2, 3) | 2 (1, 3) | 4 (4, 5) | 0.0001 |
| Day 3 | 190 | 2 (2, 3) | 2 (1, 3) | 4 (3, 5) | 0.0001 |
| Day 5 | 176 | 1 (1, 1) | 1 (0, 2) | 5 (4, 5) | 0.0001 |
| Day 1 | 202 | 3 (2, 6) | 2 (2, 3) | 8 (7, 10) | 0.0001 |
| Day 2 | 198 | 2 (2, 5) | 2 (2, 3) | 9 (6, 10) | 0.0001 |
| Day 3 | 190 | 2 (1, 4) | 2 (1, 2) | 9 (7, 10) | 0.0001 |
| Day 5 | 176 | 1 (0, 2) | 2 (1, 2) | 8 (7, 12) | 0.0001 |
| Hematological | 202 | 180 (89.1) | 143 (86.7) | 37 (100) | 0.02 |
| Hepatic | 202 | 179 (88.6) | 148 (89.7) | 31 (83.8) | 0.3 |
| Respiratory | 202 | 63 (31.2) | 26 (15.8) | 37 (100) | 0.0001 |
| Renal | 202 | 57 (28.2) | 39 (23.6) | 18 (48.6) | 0.002 |
| Cardiovascular | 202 | 43 (21.3) | 26 (15.8) | 17 (45.9) | 0.0001 |
| Neurological | 202 | 20 (9.9) | 0 (0) | 20 (54.1) | 0.03 |
| 202 | 77 (38.1) | 41 (24.8) | 36 (97.3) | 0.0001 | |
| Invasive mechanical ventilation, | 202 | 61 (30.2) | 27 (16.4) | 34 (91.9) | 0.001 |
| Duration of ventilation, days | 61 | 3 (2, 6) | 3 (2, 5) | 4 (5, 7) | 0.01 |
| HFOV, | 61 | 7 (3.5) | 2 (1.2) | 5 (13.5) | 0.0001 |
| 202 | 43 (21.3) | 26 (15.8) | 17 (45.9) | 0.0001 | |
| VIS on day 1 | 202 | 0 (0) | 0 (0) | 10 (0, 32) | 0.001 |
| VIS on day 3 | 187 | 0 (0,10) | 0 (0) | 25 (13, 81) | 0.001 |
| VIS on day 5 | 175 | 0 (0) | 0 (0) | 29 (18, 68) | 0.001 |
| 202 | 57 (28.2) | 39 (23.6) | 18 (48.6) | 0.002 | |
| RRT, | 202 | 20 (9.9) | 3 (1.8) | 17 (45.9) | 0.0001 |
| Artesunate | 202 | 61 (30.2) | 50 (30.3) | 11 (29.7) | 0.94 |
| Doxycycline | 202 | 175 (86.6) | 145 (87.9) | 30 (81.1) | 0.27 |
| Azithromycin | 202 | 20 (9.9) | 14 (8.5) | 6 (16.2) | 0.33 |
| Immunomodulation (IvIg and/or steroids) | 202 | 14 (6.9) | 8 (4.8) | 6 (16.2) | 0.01 |
| Length of PICU stay, days | 202 | 4 (3, 7) | 5 (4, 7) | 2 (1, 7) | 0.001 |
| Length of hospital stay, days | 202 | 4 (2, 7) | 5 (3, 8) | 2 (2, 4.5) | 0.001 |
All values expressed as Median (IQR).
PELOD, pediatric logistic organ dysfunction; ARDS, acute respiratory distress syndrome; AKI, acute kidney injury; VIS, Vasoactive inotrope score.
HFOV, High frequency oscillatory ventilation; RRT, Renal replacement therapy; IvIg, Intravenous immunoglobulin.
Figure 2(A) Comparison of hospital mortality and the maximum number of concurrent organ system dysfunctions. (B) Comparison of maximum number of concurrent organ system dysfunction among survivors and non survivors.
Outcome stratified by ferritin levels at admission, percentage change over 48 h and etiology.
| Dengue | 1,913 (621, 5,410) | 2,407 (569, 6,173) | 1,235 (697, 4,478) | 0.82 |
| Scrub typhus | 674 (362, 2,892) | 665 (360, 2,810) | 2,231 (418, 6,514) | 0.44 |
| Dengue and scrub typhus | 661 (459, 1,514) | 669 (378, 1,571) | - | 0.38 |
| Malaria | 619 (310, 2,131) | 500 (232, 1,685) | 3,514 (1,212, 4,116) | 0.14 |
| Enteric fever | 436 (378, 1,457) | 557 (416, 1,485) | - | 0.13 |
| No specific diagnosis | 818 (330, 3,698) | 811 (260, 3,356) | 1,077 (409, 8,239) | 0.23 |
| 183 | 148 | 35 | ||
| ≤500 | 59 (32.2) | 49 (33.1) | 10 (28.6) | 0.61 |
| >500 | 124 (67.8) | 99 (66.9) | 25 (71.4) | |
| 183 | 148 | 35 | ||
| ≤500 | 59 (32.2) | 49 (33.1) | 10 (28.6) | 0.83 |
| 501–3,000 | 78 (42.7) | 63 (42.6) | 15 (42.8) | |
| >3,000 | 46 (25.1) | 36 (24.3) | 10 (28.6) | |
| 183 | 148 | 35 | ||
| ≤300 | 34 (18.6) | 29 (19.6) | 5 (14.3) | 0.78 |
| 301–1,000 | 62 (33.9) | 51 (34.5) | 11 (31.4) | |
| 1,001–3,000 | 41 (22.4) | 32 (21.6) | 9 (25.7) | |
| 3,001–10,000 | 24 (13.1) | 20 (13.5) | 4 (11.4) | |
| >10,001 | 22 (12.0) | 16 (10.8) | 6 (17.2) | |
| 120 | 99 | 21 | ||
| Any percent increase from day 1 | 17 (14.2) | 15 (15.2) | 2 (9.6) | 0.75 |
| Percent decrease 0–25% | 23 (19.2) | 18 (18.2) | 5 (23.8) | |
| Percent decrease 26–50% | 25 (20.8) | 21 (21.2) | 4 (19) | |
| Percent decrease >50% | 55 (45.8) | 45 (45.4) | 10 (47.6) | |
All values expressed as Median (IQR).
Figure 3Box plot comparing survivors and non-survivors. (A) Ferritin levels at admission; (B) Serial ferritin levels measured on day 1 and day 3 of hospitalization; (C) Number of organ dysfunction; (D) PELOD 2scores.
Figure 4Box plot comparing those with and without NPMODS. (A) Ferritin levels at admission; (B) Serial ferritin levels measured on day 1 and day 3 of hospitalization; (C) Number of organ dysfunction; (D). PELOD 2scores.
Figure 5Receiver operating characteristic (ROC) curves comparing admission ferritin, percentage change of ferritin, PRISM III score, PELOD 2 score, and MODS score. (A) ROC for predicting 28 days mortality; (B) ROC for predicting NPMODS.